Business Context and Reporting Period
Company: Syndax Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 3, 2017 (Event Date: October 5, 2017)
Context: The Company reported a clinical milestone achievement regarding its drug candidate, entinostat, in collaboration with its exclusive sublicensee for Japan and Korea, Kyowa Hakko Kirin Co., Ltd.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a contractual milestone payment.
- Milestone Payment: $5 million (receivable from Kyowa Hakko Kirin within 30 days of patient enrollment).
Material Changes
The filing details a specific operational milestone rather than a period-over-period financial comparison. The material event is the enrollment of the first Japanese patient in a pivotal Phase 2 trial for entinostat in combination with exemestane for the treatment of advanced or recurrent hormone receptor-positive, HER2-negative breast cancer.
Outlook, Risks, and Management Commentary
Management Commentary: The Company confirmed the receipt of notice from Kyowa Hakko Kirin regarding the patient enrollment, triggering a contractual payment obligation.
Unusual Items: The $5 million milestone payment is a non-recurring event tied to the specific clinical trial progress.
Risks: The filing does not explicitly list new risks, though the reliance on clinical trial success for milestone payments is inherent to the business model described.
Investor Verification Checklist
- Verify the receipt of the $5 million milestone payment in the next quarterly financial report.
- Monitor subsequent press releases for further patient enrollment updates in the entinostat Phase 2 trial.
- Review the full text of the license agreement dated December 19, 2014, for additional potential milestone triggers.
- Confirm the status of the randomized, double-blind, placebo-controlled trial design and endpoints.